(Reuters) - Bristol-Myers on May 30 said it had agreed to pay the fine to resolve charges that it illegally concealed a patent settlement deal it had reached with Apotex Inc., a generic drugmaker based in Canada.
But privately held Apotex subsequently launched its cheaper copycat form of the drug to prevent blood clots, after the arrangement between it and Bristol-Myers collapsed due to opposition from state attorneys general in the United States.
Read more at Reuters.com Business News
But privately held Apotex subsequently launched its cheaper copycat form of the drug to prevent blood clots, after the arrangement between it and Bristol-Myers collapsed due to opposition from state attorneys general in the United States.
Read more at Reuters.com Business News
No comments:
Post a Comment